An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 1, 2015, Pages 232-237

  Baratta, Maria Giuseppina ^a,b   Schinzel, Anna C ^a,b,c   Zwang, Yaara ^a,b,c   Bandopadhayay, Pratiti ^a,b,c   Bowman Colin, Christian ^a,b   Kutt, Jennifer ^a   Curtis, Jennifer ^a   Piao, Huiying ^a   Wong, Laura C ^a   Kung, Andrew L ^a,b,d   Beroukhim, Rameen ^a,b,c   Bradner, James E ^a,b,c   Drapkin, Ronny ^a,b   Hahn, William C ^a,b,c   Liu, Joyce F ^a,b   Livingston, David M ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d NewYork Presbyterian Hospital   (United States)

Author keywords

BRD4; In vivo screen; MYCN; Ovarian cancer; Targeted therapy

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; AURORA KINASE; BRD4 PROTEIN; CYCLIN DEPENDENT KINASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MYC PROTEIN; PROTEIN; PROTEIN GALK2; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; BRD4 PROTEIN, HUMAN; NUCLEAR PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL STRAIN; CELL SURVIVAL; CONTROLLED STUDY; EPIGENETICS; FEMALE; GENE IDENTIFICATION; GENETIC SCREENING; GENETIC TRANSCRIPTION; HIGH GRADE SEROUS OVARIAN CARCINOMA; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; DRUG SCREENING; GENETIC ASSOCIATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; TUMOR CELL LINE;

MUS;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC TESTING; HUMANS; MICE; MOLECULAR TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920423504     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1422165112     Document Type: Article

References (37)

1. Romero I, Bast RC, Jr (2012) Minireview: Human ovarian cancer: Biology, current management, and paths to personalizing therapy. Endocrinology 153(4):1593-1602.
2. Ahmed AA, et al. (2010) Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 221(1):49-56.
3. Bell D, et al.; Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609-615.
4. Bowtell DDL (2010) The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 10(11):803-808.
5. Vaughan S, et al. (2011) Rethinking ovarian cancer: Recommendations for improving outcomes. Nat Rev Cancer 11(10):719-725.
6. Sheng Q, et al. (2010) An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 17(3):298-310.
7. Umene K, et al. (2013) Aurora kinase inhibitors: Potential molecular-targeted drugs for gynecologic malignant tumors. Biomed Rep 1(3):335-340.
8. Etemadmoghadam D, et al. (2013) Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer. Clin Cancer Res 19(21):5960-5971.
9. Husseinzadeh N, Husseinzadeh HD (2014) mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: A critical review. Gynecol Oncol 133(2):375-381.
10. Huddleston HG, Wong K-K, Welch WR, Berkowitz RS, Mok SC (2005) Clinical applications of microarray technology: Creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. Gynecol Oncol 96(1):77-83.
11. Li X-H, et al. (2013) Knockdown of creatine kinase B inhibits ovarian cancer progression by decreasing glycolysis. Int J Biochem Cell Biol 45(5):979-986.
12. Youn BS, et al. (2008) NM23 as a prognostic biomarker in ovarian serous carcinoma. Mod Pathol 21(7):885-892.
13. Atsumi T, et al. (2002) High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res 62(20):5881-5887.
14. Weichert W, et al. (2004) Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer 90(4):815-821.
15. Li C, Liu VW, Chiu PM, Chan DW, Ngan HY (2012) Over-expressions of AMPK subunits in ovarian carcinomas with significant clinical implications. BMC Cancer 12:357.
16. Fransson S, et al. (2012) p37δ is a new isoform of PI3K p110δ that increases cell proliferation and is overexpressed in tumors. Oncogene 31(27):3277-3286.
17. Ye Q, et al. (2014) Development of serous ovarian cancer is associated with the expression of homologous recombination pathway proteins. Pathol Oncol Res 20(4):931-938.
18. Cole C, et al. (2010) Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer Biol Ther 10(5):495-504.
19. Uhlén M, et al. (2010) Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 28(12):1248-1250.
20. Filippakopoulos P, et al. (2010) Selective inhibition of BET bromodomains. Nature 468(7327):1067-1073.
21. Zuber J, et al. (2011) RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478(7370):524-528.
22. Delmore JE, et al. (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146(6):904-917.
23. Puissant A, et al. (2013) Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov 3(3):308-323.
24. Taddei ML, Giannoni E, Comito G, Chiarugi P (2013) Microenvironment and tumor cell plasticity: An easy way out. Cancer Lett 341(1):80-96.
25. Mertz JA, et al. (2011) Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 108(40):16669-16674.
26. Dawson MA, et al. (2011) Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478(7370):529-533.
27. Lockwood WW, Zejnullahu K, Bradner JE, Varmus H (2012) Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci USA 109(47):19408-19413.
28. Bandopadhayay P, et al. (2014) BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res 20(4):912-925.
29. Shi J, et al. (2014) Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. Cancer Cell 25(2):210-225.
30. Asangani IA, et al. (2014) Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510(7504):278-282.
31. Tothill RW, et al.; Australian Ovarian Cancer Study Group (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14(16):5198-5208.
32. Helland A˚, et al.; Australian Ovarian Cancer Study Group (2011) Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS ONE 6(4):e18064.
33. Wrzeszczynski KO, et al. (2011) Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer. PLoS ONE 6(12):e28503.
34. Ciriello G, et al. (2013) Emerging landscape of oncogenic signatures across human cancers. Nat Genet 45(10):1127-1133.
35. Wyce A, et al. (2013) BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. PLoS ONE 8(8):e72967.
36. Lovén J, et al. (2013) Selective inhibition of tumor oncogenes by disruption of superenhancers. Cell 153(2):320-334.
37. Wu S-Y, Lee A-Y, Lai H-T, Zhang H, Chiang C-M (2013) Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. Mol Cell 49(5):843-857.